Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.
Anna FettiplaceJohn MarcinakMichael MerzHui-Talia ZhangLuciana KikuchiArie RegevMelissa PalmerDon C RockeyRobert FontanaPaul H HayashiHans L TillmannAdrian M Di BisceglieJames H LewisPublished in: Alimentary pharmacology & therapeutics (2024)
This review brings together evidence-based recommendations and expert opinion to provide the first dedicated consensus for best practices in detection, assessment, and management of DILI in oncology clinical trials.
Keyphrases
- clinical trial
- clinical practice
- end stage renal disease
- palliative care
- ejection fraction
- newly diagnosed
- chronic kidney disease
- primary care
- healthcare
- loop mediated isothermal amplification
- peritoneal dialysis
- label free
- real time pcr
- drug induced
- prognostic factors
- pulmonary embolism
- phase ii
- open label
- patient reported outcomes
- phase iii
- sensitive detection
- quantum dots